CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.
Diffuse Large B-cell Lymphoma
BIOLOGICAL: CTA101
Dose-limiting toxicity（DLT）, Adverse events assessed according to NCI-CTCAE v4.03 criteria, Baseline up to 35 days after T cell infusion
Overall response rate (ORR), Assessment of overall response rate for weeks 4, 12, months 6, 12, 18 and 24 in accordance with Lugano 2014 (overall response rate，OR), 4 weeks, 12 weeks, 6 months, 12 months, 18 months and 24 months|Disease control rate (DCR), Assessment of overall response rate for weeks 12, months 6, 12, 18 and 24 in accordance with Lugano 2014（disease control rate，DCR), 12 weeks, 6 months, 12 months, 18 months and 24 months
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.